mRCC (renal cell carcinoma)

Aston Group has successfully designed and launched the Registry of patients with metastatic renal cell carcinoma (mRCC).


  • Collect and analyze epidemiological and clinical data on mRCC to improve quality of treatment


  • Increase life expectancy and QoL in patients with mRCC
  • Improve diagnosis
  • Assess availability of reimbursable drugs in the regions


The Registry software facilitates monitoring of drug prescription and timely communication between physicians and patients.

Currently the Registry covers eleven regions of Russia and is being expanded to other territories.


Other registries

Project samples
CJSC Aston Consulting, 1999-2021